Spinosad Lufenuron Oral Formulation for Flea Control Without Emesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current flea control treatments for domestic animals, such as those containing lufenuron and spinosad, often result in emesis (vomiting) and lead to flea resistance, necessitating a solution for extended control without toxic side effects.
Innovation Solution
A single-dose oral formulation combining spinosad and an insect growth regulator like lufenuron, administered at lower concentrations than previously thought necessary, providing up to 100% efficacy against fleas for a month without causing vomiting.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If lufenuron is administered at ordinary dosage (30 mg/kg in cats, 10 mg/kg in dogs) for flea control, then flea control efficacy is achieved, but emesis occurs as a common side effect
Solution Approach 1:
The patent combines spinosad (an insecticide that kills adult fleas) with lufenuron (an insect growth regulator that prevents flea development) into a single formulation. This combination allows for reduced dosage of lufenuron while maintaining efficacy, thereby reducing emesis. The synergistic effect of combining two different mechanisms of action enables better flea control with fewer side effects.
Solution Approach 2:
The patent changes the dosage parameters of lufenuron from ordinary levels (30 mg/kg in cats, 10 mg/kg in dogs) to reduced levels when combined with spinosad. By adjusting the concentration and dosage regimen, the patent achieves effective flea control while minimizing the emetic side effect, demonstrating parameter optimization to resolve the contradiction between efficacy and tolerability.
2Reliability
If spinosad is administered alone at high dosage (30-60 mg/kg) to kill adult fleas, then immediate flea killing is achieved, but emesis occurs in excess of 12% of animals
Solution Approach 1:
The patent merges spinosad with lufenuron in a single formulation, where spinosad provides immediate adult flea killing and lufenuron provides ongoing prevention of flea development. This combination allows for reduced spinosad dosage while maintaining adult flea control efficacy, thereby reducing emesis incidence from over 12% to lower levels.
Solution Approach 2:
The patent establishes continuous flea control by combining the immediate killing action of spinosad with the sustained growth-regulating action of lufenuron. This continuous action at reduced dosages maintains efficacy while reducing peak concentrations that cause emesis, resolving the contradiction between immediate effect and side effect reduction.
3Reliability
If conventional flea control chemicals (carbamates, organophosphates, pyrethrins, pyrethroids) are used, then flea killing is achieved, but toxic side effects occur and resistance develops
Solution Approach 1:
The patent changes the chemical parameters by using spinosad, a naturally derived fermentation product, instead of conventional synthetic chemicals. This parameter change in chemical composition provides effective flea killing with reduced toxicity and resistance development, as spinosad has a different mode of action and favorable safety profile compared to traditional flea control agents.
Data Source
AI summary
A single-dose oral formulation of spinosad and lufenuron and methods for its use in the extended control of a flea infestation on a domestic animal such as a dog without emesis.